This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 44/2/195    most recent 01.HYP.0000132883.20764.12v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelly, D. J. Articles by Gilbert, R. E. Search for Related Content PubMed PubMed Citation Articles by Kelly, D. J. Articles by Gilbert, R. E. Related Collections Remodeling Cardiovascular Pharmacology ACE/Angiotension receptors Other Vascular biology

(Hypertension. 2004;44:195.)
© 2004 American Heart Association, Inc.

Scientific Contributions

Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo

Darren J. Kelly; Alison J. Cox; Renae M. Gow; Yuan Zhang; Bruce E. Kemp; Richard E. Gilbert

From the University of Melbourne (D.J.K., A.J.C., R.M.G., Y.Z., R.E.G.), Department of Medicine, St. Vincent’s Hospital, and St. Vincent’s Institute of Medical Research (B.E.K.), Victoria, Australia.

Correspondence to Professor Richard E. Gilbert, University of Melbourne Department of Medicine, St. Vincent’s Hospital, 41 Victoria Parade, Fitzroy, Victoria, 3065, Australia. E-mail gilbert{at}medstv.unimelb.edu.au

In addition to the modulation of vascular tone, angiotensin II (Ang II) has growth factor–like effects in vascular tissue. The mechanisms whereby Ang II mediates these trophic actions are incompletely understood but are thought to include effects on systemic blood pressure, stimulation of transforming growth factor-ß (TGF-ß) expression, and transactivation of growth factor receptor kinases. To investigate the role of platelet-derived growth factor receptor (PDGFR) transactivation in mediating the growth factor–like effects of Ang II we administered Ang II (200 ng/kg per minute) or saline to male Sprague-Dawley rats by osmotic minipump for 12 days and treated with imatinib mesylate, an inhibitor of the PDGFR tyrosine kinase. In addition to systolic blood pressure elevation, Ang II infusion led to increased vascular weight, media:lumen ratio, matrix expansion, and overexpression of TGF-ß mRNA in mesenteric arteries. Without affecting blood pressure or PDGF ligand expression, imatinib attenuated the changes in vessel morphology but further increased TGF-ß mRNA. Western blot analysis of mesenteric arterial tissue demonstrated the presence of the ß- but not the -isoform of PDGFR. Phosphorylation of PDGFR-ß was increased by Ang II in vascular smooth muscle cells, and this was inhibited by imatinib. The findings of attenuation of vascular hypertrophy and matrix deposition by imatinib indicate that transactivation of the PDGFR in vivo contributes to the growth factor–like effects of Ang II, independent of its hemodynamic effects or its ability to induce TGF-ß gene expression.

Key Words: angiotensin II • platelet-derived growth factor • transforming growth factors • vascular diseases

This article has been cited by other articles:

				M. Brama, S. Basciani, S. Cherubini, S. Mariani, S. Migliaccio, M. Arizzi, G. Rosano, G. Spera, and L. Gnessi Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment Endocr. Relat. Cancer, March 1, 2007; 14(1): 61 - 72. [Abstract] [Full Text] [PDF]

				A. C. Snider and K. E. Meier Receptor transactivation cascades. Focus on "Effects of {alpha}1D-adrenergic receptors on shedding of biologically active EGF in freshly isolated lacrimal gland epithelial cells" Am J Physiol Cell Physiol, January 1, 2007; 292(1): C1 - C3. [Full Text] [PDF]

				M. Ushio-Fukai and R. W. Alexander Caveolin-Dependent Angiotensin II Type 1 Receptor Signaling in Vascular Smooth Muscle Hypertension, November 1, 2006; 48(5): 797 - 803. [Full Text] [PDF]

				M. W.M. Schellings, M. Baumann, R. E.W. van Leeuwen, R. F.J.J. Duisters, S. H.P. Janssen, B. Schroen, C. J. Peutz-Kootstra, S. Heymans, and Y. M. Pinto Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats Hypertension, March 1, 2006; 47(3): 467 - 474. [Abstract] [Full Text] [PDF]

				H. Suzuki and S. Eguchi Growth Factor Receptor Transactivation in Mediating End Organ Damage by Angiotensin II Hypertension, March 1, 2006; 47(3): 339 - 340. [Full Text] [PDF]

				M. Wang, J. Zhang, G. Spinetti, L.-Q. Jiang, R. Monticone, D. Zhao, L. Cheng, M. Krawczyk, M. Talan, G. Pintus, et al. Angiotensin II Activates Matrix Metalloproteinase Type II and Mimics Age-Associated Carotid Arterial Remodeling in Young Rats Am. J. Pathol., November 1, 2005; 167(5): 1429 - 1442. [Abstract] [Full Text] [PDF]

				M. Ushio-Fukai, L. Zuo, S. Ikeda, T. Tojo, N. A. Patrushev, and R. W. Alexander cAbl Tyrosine Kinase Mediates Reactive Oxygen Species- and Caveolin-Dependent AT1 Receptor Signaling in Vascular Smooth Muscle: Role in Vascular Hypertrophy Circ. Res., October 14, 2005; 97(8): 829 - 836. [Abstract] [Full Text] [PDF]

				D. J. Kelly, A. Chanty, R. M. Gow, Y. Zhang, and R. E. Gilbert Protein Kinase C{beta} Inhibition Attenuates Osteopontin Expression, Macrophage Recruitment, and Tubulointerstitial Injury in Advanced Experimental Diabetic Nephropathy J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1654 - 1660. [Abstract] [Full Text] [PDF]